

SUPPLEMENTAL TABLE 1 Overview of the number of patients that received both ^{177}Lu and ^{90}Y

Number of cycles		^{90}Y				
		1	2	3	4	5
^{177}Lu	1	0	78	37	8	1
	2	78	71	4	0	0
	3	77	13	1	0	0
	4	6	0	0	0	0
	5	0	0	0	0	0

* 22 patients were excluded from this table, these patients received both ^{177}Lu and ^{90}Y within one cycle

SUPPLEMENTAL TABLE 2 Other parameters evaluated for progression free survival. HR > 1 indicates a greater risk for progression and HR < 1 a lower risk.

Parameter	Group	Univariate			Multivariate		
		HR	95% CI	p-value	HR	95% CI	p-value
Location primary tumor	Small intestine	1		0.062 [†]	-		
	CUP	1.155	0.890-1.497				
	Pancreas	1.162	0.954-1.415				
	Other	1.289	0.958-1.735				
	Large intestine	1.292	0.908-1.837				
	Lung	1.625	1.186-2.226				
Tumor grade	Grade 1	1		0.036 [†]	-		
	Grade 2	1.224	0.999-1.500				
	Grade 3	1.522	1.062-2.180				
Ki-67	Q1: <2 %	1		0.002 [†]	1		0.044
	Q2: 2-5%	1.165	0.898-1.513		1.171	0.880-1.557	
	Q3: 5-10%	1.466	1.111-1.934		1.419	1.041-1.935	
	Q4: >10%	1.631	1.230-2.163		1.493	1.090-2.045	
Functional tumor	Yes	1.052	0.873-1.269	0.595	-		
Performance status	WHO 0	1		<0.001 [†]	-		
	WHO 1	1.352	1.127-1.623				
	WHO 2-3	1.741	1.262-2.402				
Comorbidities	Hypertension	0.842	0.624-1.135	0.258	-		
	Diabetes	1.373	0.989-1.907	0.058 [†]			
Prior treatment	Resection primary tumor	0.997	0.849-1.172	0.972	-		
	Somatostatin analogue	1.162	0.989-1.367	0.069 [†]	-		
	Chemotherapy	1.362	1.123-1.652	0.002 [†]	1.375	1.039-1.820	0.026
	Ablation	1.090	0.864-1.374	0.467	-		
	Interferon- α	1.487	1.046-2.114	0.027 [†]	2.054	1.211-3.485	0.008
	Radiotherapy	2.059	1.420-2.984	<0.001 [†]	-		
Isotope	¹⁷⁷ Lutetium	1		0.028 [†]	-		
	¹⁷⁷ Lu & ⁹⁰ Y	0.797	0.672-0.944				
	⁹⁰ Yttrium	0.823	0.642-1.055				
Blood count	Normal	0.927	0.783-1.098	0.381	-		
CgA (μg/l)	Q1: <112	1		<0.001 [†]	1		<0.001
	Q2: 112-333	1.189	0.932-0.517		1.267	0.922-1.741	
	Q3: 336-1168	1.580	1.241-2.011		1.469	1.084-1.992	
	Q4: >1168	2.148	1.679-2.747		2.039	1.488-2.794	
Serotonin		1	1.000-1.000	0.493	-		
eGFR		0.999	0.996-1.003	0.690	-		
Creatinine		1.002	0.998-1.006	0.270	-		

HR = Hazard Ratio

CI = Confidence Interval

[†]p<0.01 parameter used as input for multivariate analysis

SUPPLEMENTAL TABLE 3 Other parameters evaluated for overall survival. HR > 1 indicates a greater risk for death of any cause and HR < 1 a lower risk.

Parameter	Group	Univariate			Multivariate		
		HR	95% CI	p-value	HR	95% CI	p-value
Location primary tumor	Small intestine	1		0.014 [†]	-		
	CUP	1.197	0.848-1.691				
	Other	1.413	0.968-2.062				
	Pancreas	1.519	1.184-1.948				
	Large intestine	1.594	1.003-2.533				
	Lung	1.716	1.150-2.560				
Tumor grade	Grade 1	1		<0.001 [†]	-		
	Grade 2	1.394	1.065-1.826				
	Grade 3	2.473	1.621-3.772				
Ki-67	Q1: <2 %	1		0.001 [†]	1		0.014
	Q2: 2-5%	1.340	0.960-1.871		1.363	0.946-1.965	
	Q3: 5-10%	1.519	1.051-2.194		1.203	0.798-1.814	
	Q4: >10%	2.143	1.488-3.087		1.930	1.285-2.899	
Performance status	WHO 0	1		<0.001 [†]	1		0.010
	WHO 1	1.781	1.432-2.214		1.551	1.109-2.169	
	WHO 2-3	2.817	1.941-4.089		2.305	1.432-3.713	
Functional	Yes	0.865	0.675-1.108	0.251	-		
Comorbidities	Hypertension	0.927	0.616-1.396	0.716	-		
	Diabetes	1.184	0.777-1.805	0.431	-		
Prior treatment	Resection primary tumor	0.715	0.584-0.877	0.001 [†]	-		
	Somatostatin analogue	1.159	0.949-1.417	0.148	-		
	Ablation	1.458	1.103-1.928	0.008 [†]	1.519	1.041-2.215	0.030
	Interferon- α	1.504	1.002-2.256	0.049 [†]	-		
	Radiotherapy	1.780	1.120-2.829	0.015 [†]	-		
	Chemotherapy	1.792	1.434-2.239	<0.001 [†]	1.979	1.412-2.773	<0.001
Isotope	¹⁷⁷ Lutetium	1		0.110	-		
	⁹⁰ Yttrium	0.843	0.627-1.133				
	¹⁷⁷ Lu & ⁹⁰ Y	0.792	0.636-0.986				
Blood count	Normal	0.732	0.593-0.903	0.004 [†]	-		
CgA (μg/l)	Q1: <112	1		<0.001 [†]	1		<0.001
	Q2: 112-336	1.531	1.100-2.131		1.690	1.095-2.608	
	Q3: 336-1168	1.887	1.354-2.631		1.816	1.718-2.799	
	Q4: >1168	3.357	2.434-4.631		2.671	1.717-4.155	
Serotonin		1.000	1.000-1.000	0.567	-		
eGFR		1.002	0.998-1.006	0.236	-		
Creatinine		0.998	0.994-1.003	0.510	-		

HR = Hazard Ratio

CI = Confidence Interval

[†]p<0.01 parameter used as input for multivariate analysis